MedTrace Logo

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

NCT02248844 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 667

Last updated 2019-07-05

No results posted yet for this study

Summary

This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet Lines

Interventions

BIOLOGICAL

Botulinum Toxin Type A

Botulinum toxin Type A injected into crow's feet line areas per clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-26
Primary Completion
2017-08-14
Completion
2017-08-14

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248844 on ClinicalTrials.gov